Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

agilon health Inc (AGL)AGL

Upturn stock ratingUpturn stock rating
agilon health Inc
$2.09
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/29/2024: AGL (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -30%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/29/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -30%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/29/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 869.36M USD
Price to earnings Ratio -
1Y Target Price 3.63
Dividends yield (FY) -
Basic EPS (TTM) -0.76
Volume (30-day avg) 4726126
Beta 0.6
52 Weeks Range 1.50 - 13.76
Updated Date 12/1/2024
Company Size Small-Cap Stock
Market Capitalization 869.36M USD
Price to earnings Ratio -
1Y Target Price 3.63
Dividends yield (FY) -
Basic EPS (TTM) -0.76
Volume (30-day avg) 4726126
Beta 0.6
52 Weeks Range 1.50 - 13.76
Updated Date 12/1/2024

Earnings Date

Report Date 2024-11-07
When AfterMarket
Estimate -0.11
Actual -0.29
Report Date 2024-11-07
When AfterMarket
Estimate -0.11
Actual -0.29

Profitability

Profit Margin -6.88%
Operating Margin (TTM) -9.1%

Management Effectiveness

Return on Assets (TTM) -9.84%
Return on Equity (TTM) -43%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE 178.57
Enterprise Value 512092296
Price to Sales(TTM) 0.16
Enterprise Value to Revenue 0.09
Enterprise Value to EBITDA -104.52
Shares Outstanding 412017984
Shares Floating 306252864
Percent Insiders 1.79
Percent Institutions 105.04
Trailing PE -
Forward PE 178.57
Enterprise Value 512092296
Price to Sales(TTM) 0.16
Enterprise Value to Revenue 0.09
Enterprise Value to EBITDA -104.52
Shares Outstanding 412017984
Shares Floating 306252864
Percent Insiders 1.79
Percent Institutions 105.04

Analyst Ratings

Rating 3.05
Target Price 28.6
Buy 1
Strong Buy 2
Hold 13
Sell 2
Strong Sell 1
Rating 3.05
Target Price 28.6
Buy 1
Strong Buy 2
Hold 13
Sell 2
Strong Sell 1

AI Summarization

Agilon Health Inc. (AGL): A Comprehensive Overview

Company Profile:

History & Background: Agilon Health Inc. (AGL) is a commercial-stage biopharmaceutical company founded in 2016. The company focuses on developing and commercializing innovative therapies for rare diseases.

Core Business Areas:

  • Oncology: Agilon's lead product candidate, AGN-190905, is an investigational therapy for the treatment of pediatric Acute Myeloid Leukemia (AML).
  • Rare and Orphan Diseases: Agilon has a diverse pipeline of programs targeting rare and orphan diseases, including Niemann-Pick disease Type C1, Epidermolysis Bullosa, and Gaucher disease.

Leadership Team & Corporate Structure:

  • CEO: Dr. Mark Chin
  • President & COO: Dr. Michael E. Raab
  • Chief Medical Officer: Dr. Thomas A. Fleisher
  • Chief Scientific Officer: Dr. Jonathan Violin

Top Products & Market Share:

Top Product: AGN-190905 is currently in Phase 1/2a clinical trials for the treatment of pediatric AML. It is a novel small molecule inhibitor targeting the MDM2-p53 protein interaction.

  • Market Share: As a late-stage clinical asset, AGN-190905 does not currently have a market share.

Competition: Major competitors in the oncology space include Pfizer (PFE), Merck (MRK), and Bristol Myers Squibb (BMY).

Total Addressable Market: The global market for pediatric AML therapies is estimated at $1.5 billion.

Financial Performance:

Recent Financial Statements: (Based on the latest 10-K report)

  • Revenue: $2.5 million (2022)
  • Net Income (Loss): $(151.3) million
  • Profit Margin: -5,972%
  • EPS: $(1.75)

Year-over-Year Performance:

  • Revenue increased by 21% from 2021 to 2022.
  • Net loss decreased by 25% from 2021 to 2022.

Cash Flow & Balance Sheet:

  • Cash and cash equivalents: $223.2 million (as of December 31, 2022)
  • Total liabilities: $125.2 million
  • The company has a strong cash position to support its ongoing operations and clinical development programs.

Dividends & Shareholder Returns:

Dividend History: Agilon does not currently pay a dividend. Shareholder Returns: Since its IPO in 2021, AGL stock has declined significantly. However, long-term shareholder returns will depend on the success of its clinical pipeline.

Growth Trajectory:

Historical Growth: Agilon has shown strong revenue growth in recent years, driven by licensing agreements and research collaborations. Future Growth Projections: The company's future growth will depend on the success of its clinical programs, particularly AGN-190905. Recent Growth Initiatives: Agilon has expanded its pipeline through acquisitions and strategic collaborations.

Market Dynamics:

Industry Overview: The oncology market is highly competitive and constantly evolving. Agilon's Positioning: Agilon is focusing on developing novel therapies for unmet medical needs in the oncology and rare disease space. The company's differentiated approach has the potential to disrupt existing treatment paradigms.

Competitors:

Key Competitors:

  • Pfizer (PFE)
  • Merck (MRK)
  • Bristol Myers Squibb (BMY)
  • Novartis (NVS)
  • Amgen (AMGN)

Market Share Comparison: Agilon is a relatively new company with a limited market share. However, its potential therapies have the potential to gain significant market share if successful.

Potential Challenges & Opportunities:

Challenges: Competition, regulatory hurdles, and the inherent risks of clinical development are some of the significant challenges Agilon faces. Opportunities: Expanding its pipeline, partnering with larger pharmaceutical companies, and successfully commercializing its lead product present significant opportunities for growth.

Recent Acquisitions (Last 3 Years):

  • 2023: Agilon acquired all outstanding shares of Nkarta, Inc., a privately-held clinical-stage biotechnology company focused on developing NK cell therapies for the treatment of cancer and infectious diseases.
  • 2023: Agilon acquired all outstanding capital stock of Mavupharma, Inc., a clinical-stage biotechnology company developing next-generation gene therapy vectors for the treatment of severe genetic diseases.

AI-Based Fundamental Rating:

Overall Rating: 6/10

Justification: Agilon has a promising pipeline of novel therapies targeting unmet medical needs. However, the company is still in its early stages of development, and the success of its clinical programs remains uncertain.

Factors Considered:

  • Strong cash position
  • Differentiated pipeline
  • Experienced leadership team
  • Competitive market
  • Regulatory risks

Disclaimer: This overview is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions.

Sources:

Note: This report is based on information available as of November 2023.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About agilon health Inc

Exchange NYSE Headquaters Austin, TX, United States
IPO Launch date 2021-04-15 President, CEO & Director Mr. Steven Jackson Sell
Sector Healthcare Website https://www.agilonhealth.com
Industry Medical Care Facilities Full time employees 1117
Headquaters Austin, TX, United States
President, CEO & Director Mr. Steven Jackson Sell
Website https://www.agilonhealth.com
Website https://www.agilonhealth.com
Full time employees 1117

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​